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Abstract In animal systems, indomethacin inhibits cAMP
production via a prostaglandin-adenylyl cyclase pathway. To
examine the possibility that a similar mechanism occurs in
plants, the effect of indomethacin on the cell cycle of a tobacco
bright yellow 2 (TBY-2) cell suspension was studied. Application
of indomethacin during mitosis did not interfere with the M/G1
progression in synchronized BY-2 cells but it inhibited cAMP
production at the beginning of the G1 phase and arrested the cell
cycle progression at G1/S. These observations are discussed in
relation to the putative involvement of cAMP biosynthesis in the
cell cycle progression in TBY-2 cells.
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1. Introduction
Fluctuations of cyclic AMP (cAMP) concentrations repre-
sent an important means of signal transduction during the cell
cycle progression in animals and yeast. Depending on the cell
type, £uctuation in cAMP levels can lead to either stimulatory
or inhibitory e¡ects [1^3]. In yeast, the Ras/cAMP [4^6] path-
way plays a central role in co-ordinating cell growth and
metabolism. Cells de¢cient in cAMP dependent protein kinase
(PKA) arrest in G1 [4]. In an astrocytic cell line, cAMP in-
hibits cyclin dependent kinase (CDK)-cyclin complexes in the
G1 phase of the cycle [7].
Data on the presence of cAMP in higher plants are contin-
uously emerging since 25 years, but the functional role of this
molecule is still poorly de¢ned and as a result, the ‘cAMP
controversy’ remains unresolved [8^12]. In the lower plant
Euglena gracilis, cAMP and its metabolic components were
shown to be key regulators of the circadian rhythm driven
cell cycle [13,14]. In the embryos and seedlings of Haplopappus
gracilis, inhibition of the cAMP degradative enzyme phospho-
diesterase by aminophylline results in a cell cycle block in the
G1 and G2 phase [15].
In a tobacco bright yellow 2 (TBY-2) cell suspension, cul-
ture accumulation of cAMP has been shown to correlate with
the S and G1 phase of the cell cycle [16]. Furthermore, it was
shown that the addition of indomethacin, which has been
extensively studied as an inhibitor of prostaglandin dependent
adenylyl cyclase and cAMP dependent protein kinase activity
in animal cells [17^20], simultaneously prevents the accumu-
lation of cAMP in the S phase and arrests the cells in the G2/
M phases of the cycle [16]. These ¢ndings were in accordance
with data showing that in lymphocytes, indomethacin arrests
DNA synthesis by the inactivation of adenyl cyclase activity
[18], whereas in rat hepatoma cells and human diploid ¢bro-
blast cells, addition of indomethacin blocked the cell cycle at
the G1 phase [21,22].
Highly synchronous cell populations are required to study
the regulatory events of the cell cycle. From this point of view,
the TBY-2 cell suspension culture provides valuable advan-
tages in plant cell cycle research because of its fast growth rate
and high synchronization potential [23]. By using di¡erent cell
cycle blocks as a tool for synchronization, this cell suspension
culture o¡ers unique opportunities to study the genetic and
biochemical events of the plant cell cycle. In this paper, we
report on the e¡ect of indomethacin, when exogenously ap-
plied during mitosis of propyzamide-synchronized BY-2 cells,
on both the inhibition of cAMP biosynthesis in G1 and pro-
gression through M, M/G1, G1 and arrest in G1/S.
2. Material and methods
2.1. TBY-2 synchronization and sampling
TBY-2 cell cultures were maintained as described by Nagata et al.
[23]. In brief, 1.5 ml of stationary culture was transferred to 100 ml of
MS medium (30 g/ml sucrose, 0.2 g/ml KH2PO4, 4.302 g/ml MS) and
cultured for 7 days. Depending on the aim of the experiment, either a
sequential aphidicolin-propyzamide or an aphidicolin-oryzalin block
was performed. 10^15 ml of stationary culture was transferred to
100 ml of MS medium containing 5 Wg/ml aphidicolin (ICN). Aphi-
dicolin-treated cells were extensively washed and released in 100 ml of
fresh medium after 24 h. In this synchronization system, parallel
studies were performed by treating cells with indomethacin at a con-
centration of 10 Wg/ml and indomethacin+aphidicolin for 24 h in
order to compare the e¡ect of indomethacin with aphidicolin. To
observe the e¡ect of indomethacin on the M to G1 transition, we
delivered indomethacin (10 Wg/ml) at the time of the mitotic peak,
6 h after the cells were released from aphidicolin. Samples were col-
lected every hour in order to perform mitotic index and £ow cyto-
metric measurements.
In a ¢rst attempt to obtain a higher synchronization, we applied
oryzalin (15 WM) at the end of the G2 phase in aphidicolin-released
cells [24]. Because of experimental problems related to the use of
oryzalin (see Section 3), we later delivered propyzamide (1.54 Wg/ml)
during the G2 phase (about 4 h after aphidicolin release). When al-
most all cells were synchronized in the prometaphase [16], propyz-
amide was removed by extensive washing. To observe the e¡ect of
indomethacin on the G1 and G1/S phase, one part of propyzamide-
released cells was treated with indomethacin (1.54 Wg/ml) while the
other part was not treated. Samples were collected every hour for
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mitotic index, Northern analysis and £ow cytometric analysis and
cAMP analysis. Cells were left to sediment on ice and the supernatant
was carefully removed. Samples were frozen in liquid nitrogen and
kept at 380‡C until analysis.
2.2. Mitotic index, Northern analysis, nuclei isolation and £ow
cytometry
Fixed cells (ethanol:acetic acid, 3:1, v/v) were stained with 5 WM
4P,6-diamidino-2-phenylindole (DAPI, Molecular Probes, USA) and
analyzed using a £uorescent microscope (Leitz, Germany) by counting
the number of nuclei (300 cells) in the late prophase to telophase.
Fluorescein diacetate (5 Wg/ml) was used for viability staining. Total
RNA was prepared according to the method described by Goodall et
al. [25]. RNA blots were hybridized at 65‡C in a phosphate bu¡er in
the presence of 50% formamide to random-primed 32P probes corre-
sponding to the coding region of the Arabidopsis thaliana H4A748
gene and cyclin A59 gene [26,27]. For nuclei puri¢cation, we con-
ducted enzymatic treatment according to [28]. Samples were stored
at 4‡C until further analysis by £ow cytometry. On the day of anal-
ysis, isolated nuclei were treated with RNAse A, stained with propi-
dium iodide (50 Wg/ml) and analyzed with a FACS scan £ow cytom-
eter.
2.3. cAMP extraction, puri¢cation and quanti¢cation
For cAMP extraction and puri¢cation, we followed the method
described in Ehsan et al. [16] with little modi¢cation. In brief, 200^
400 mg of cells was ground with a mortar and pestle in liquid nitrogen
and homogenized in an ice-cold mixture of methanol:chloroform:1 M
formic acid (12:5:3, v/v/v) containing 585 Bq [3H]2P,8-3P,5P-cAMP as
an internal standard. The samples were immuno-a⁄nity-puri¢ed ac-
cording to Roef et al. [29] and stored at 320‡C until further analysis.
Immuno-a⁄nity-puri¢ed samples were quanti¢ed according to the
method described in Witters et al. [30].
3. Results
3.1. Progression from the M to G1 phase is not a¡ected by
indomethacin
In an attempt to establish whether indomethacin has an
e¡ect during the transition from M to G1, we applied indo-
methacin at the time of the mitotic peak (6 h) in aphidicolin-
released cells (Fig. 1). In the control culture, cells progressed
from the M phase to G1 in 1 h. Indomethacin-treated cells
proceeded at a comparable rate (Fig. 1a), although the £ow
cytometric analysis showed that some cells remain in the G2/
M phase of the cycle. These are probably cells from a pop-
ulation that is still in S or G2 at the time of application of
indomethacin [16]. From MI measurements (Fig. 1b), it can
be seen that cells that were engaged in mitosis proceeded to
the G1 phase. Thus, indomethacin showed no inhibitory ac-
tion on M/G1 progression.
3.2. G1/S phase arrest in indomethacin-treated BY-2 cells
Freshly diluted stationary cells, which were in G1 (Fig. 2a),
were withheld in G1 for 96% after a 24 h treatment with
indomethacin (10 Wg/ml) (Fig. 2c). Aphidicolin treatment for
24 h resulted in S phase arrest (Fig. 2b). Addition of aphidi-
colin+indomethacin for 24 h resulted in G1 block (Fig. 2d) as
was the case when only indomethacin was added (Fig. 2c).
This shows that indomethacin induces cell cycle arrest before
the aphidicolin block in S.
The synchronicity of aphidicolin-released cells was not high
enough (MI = 30^50%) to study a second cell division cycle.
Therefore, we blocked the cells for 24 h with aphidicolin.
Subsequently, we applied di¡erent M phase blocks to these
aphidicolin-released cells (Fig. 3). When we delivered oryzalin
(which inhibits microtubule polymerization) at a concentra-
tion of 15 WM, almost 90% cells blocked at the metaphase
(Fig. 3a). When we removed this drug by washing in order
to observe the progression from the M to G1 phase of the
cycle, major di⁄culties arose. About 25% of the cells were still
in the M phase 2 h after oryzalin release and more than 10%
Fig. 1. E¡ect of indomethacin on M/G1 progression. Indomethacin
was delivered at the time of the mitotic peak (6 h) in aphidicolin-re-
leased cells. Cell cycle progression was determined by £ow cytomet-
ric analysis (a, left : control cells ; right: indomethacin-treated cells)
and the mitotic index (b). The dot plot (top right) represents a cyto-
gram of the width versus area £uorescence of the DNA signal of in-
domethacin-treated cells. Only dots within the region displayed are
included in the histogram analysis.
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remained in M for at least 8 h (Fig. 3a). Compared to control
cells, the size of the nuclei was considerably larger (Fig. 3b)
and most important, cells were not amenable to £ow cytomet-
ric analysis. No such problems were encountered when pro-
pyzamide (which also inhibits microtubule polymerization)
was used. Upon application of this compound at a concen-
tration of 1.54 Wg/ml to aphidicolin-released cells, we obtained
90% synchronization (metaphase block). All of these cells
reached the G1 phase within 2 h after washing o¡ the propyz-
amide (Fig. 3a). We added indomethacin to these highly
synchronized aphidicolin/propyzamide-released cells to ob-
serve whether indomethacin has any e¡ect on the progression
through the G1 and S phase of the cycle. The indomethacin-
treated cells proceeded from the M to G1 phase in the same
fashion as the control cells did, but remained blocked in G1
(Fig. 4a). The expression of the S phase markers histone H4
and cyclin A59 showed a clear G1/S block in indomethacin
treated cells (Fig. 4b). Viability tests in indomethacin-treated
cells showed no signi¢cant di¡erences compared to the control
cells (data not shown).
3.3. Inhibition of cAMP accumulation by indomethacin
A £uctuation of cAMP levels during the cell cycle is a part
of the series of events for proper cell cycle progression in
animal systems [18]. In this study, we investigated whether
the G1/S block by indomethacin is related to inhibition of
cAMP accumulation in the G1 phase. Therefore, we analyzed
cAMP concentrations in indomethacin-treated cells at di¡er-
ent time points in the G1 phase. Our results show that in
control cultures, an accumulation of cAMP was observed
whereas in indomethacin-treated cells, cAMP accumulation
was inhibited at the beginning of G1 (Fig. 5). The cAMP
peak in the control culture corresponds to 24 pmol/gfw at
this time point.
4. Discussion
TBY-2 cell suspension cultures have been extensively used
during the last few years for plant cell cycle analysis. This
highly synchronizable cell line has not only facilitated the
dissection of the molecular machinery of the plant cell cycle
but also the identi¢cation of the e¡ect of di¡erent compounds
on it. An interesting ¢nding in the present study is the e¡ect of
oryzalin on this BY-2 cell line where perhaps nuclear poly-
ploidy occurs. However, our objective was to reach a higher
synchronization and we therefore proceeded our investigation
by using propyzamide. In contrast to oryzalin-treated cells,
propyzamide-exposed cells showed no abnormal morpholog-
ical changes.
The role of regulatory components during plant cell cycle
progression is still much less understood compared to animal
cells [31,32]. In all eukaryotes, two important control points
exist (G1/S and G2/M) where CDK-cyclin complexes are ma-
jor phosphorylation players. The G1/S is a key regulatory
point where the cell decides whether or not to enter the
DNA replication step. Hence, molecules that inhibit G1/S
phase progression have been considered to be excellent candi-
dates not only for controlling the cell cycle but also to dissect
Fig. 2. Flow cytometric analysis of the DNA content in indomethacin/aphidicolin-treated cells. a: Control cells in a stationary culture; b: aphi-
dicolin-treated cells ; c: indomethacin-treated cells and d: indomethacin+aphidicolin-treated cells.
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the molecular mechanism underlying this important phase.
Northern analysis of histone H4, cyclin A expression levels
and £ow cytometric analysis of indomethacin-treated cells
gave a clear picture of G1/S inhibition. This demonstrates
that besides the described reversible inhibition of growth of
animal cells in the G1 phase [21,22], indomethacin also blocks
TBY-2 cells at the G1/S phase. The addition of indomethacin
during the M phase did not retard the progression from the
M/G1 phase of the cycle. This is in contrast with animal cells,
where the cAMP/PKA pathway is necessary for M/G1 tran-
sition [33]. Our observation is supported by our previous
study where no cAMP peak was detected during the M phase
of the cycle in aphidicolin-released TBY-2 cells [16]. The
present study shows, for the ¢rst time, that indomethacin in-
hibits plant cell cycle progression in the G1/S phase. Still, its
functional pathway needs to be documented.
Our ¢ndings not only demonstrated the e¡ect of indome-
thacin during the cell cycle but also £uctuations of plant
cAMP during the cell cycle progression. cAMP is involved
Fig. 3. E¡ect of oryzalin in TBY-2 cells. a: Mitotic index of oryza-
lin- and propyzamide-treated cells. b: Light microscopic analysis of
oryzalin-treated cells (upper) and control cells (lower). Scale bar in-
dicates 50 Wm.
Fig. 4. a: Flow cytometric analysis of indomethacin-treated cells at
2 h intervals (T4-T10). Left: control cells (aphidicolin/propyzamide-
released). Right: indomethacin-treated cells (aphidicolin/propyz-
amide-released). b: Northern analysis of cyclin A (upper) and H4
(lower) expression levels in control and indomethacin-treated cells at
2 h intervals (0^10) after aphidicolin/propyzamide release.
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in the regulation of a wide variety of developmental processes
in animal and yeast. In these systems, cAMP either blocks or
promotes cell cycle progression in the mid to late G1 phase
[1,34,35]. For example, it was demonstrated that PKA phos-
phorylates cyclin D1 at Ser-90 in the cyclin box and induces
p27 (CDK inhibitor) in an animal system [36,37]. Induction of
cyclin A in the restriction point by cAMP and suppression by
PKA inhibitors has been reported in human ¢broblast cell
lines [38]. In our investigation, the oscillation of cAMP at
the beginning of the G1 phase as well as its inhibition by
indomethacin raised intriguing questions for the possible in-
volvement of cAMP for proper cell cycle progression.
Although not known, we can assume that the e¡ects of indo-
methacin on cAMP production at the beginning of the G1
phase a¡ect the complex mechanism by which cells blocked
at the G1/S phase of the cycle.
In higher plants, the putative involvement of cAMP during
the plant cell cycle is largely unknown. However, there is
increasing evidence of the involvement/£uctuation of cAMP
during the cell cycle from lower to higher plants. PKA has not
yet been clearly documented but other components involved
in cAMP action are described in plant cells. For example,
putative cAMP response element binding proteins and an ad-
enylyl cyclase-associated protein have been identi¢ed in higher
plants [39,40]. Here, we provide data for the presence of
cAMP in the G1 phase and the inhibition of cAMP in the
beginning of the G1 phase by indomethacin. This strengthens
our believe in the necessity of cAMP for proper cell cycle
progression.
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